On Friday, Shares of Hertz Global Holdings, Inc. (NYSE:HTZ), gained 5.32% to $20.60.
Hertz Global Holdings, declared that it is soliciting consents from holders of its and its wholly-owned partner, Hertz Holdings Netherlands B.V.’s (“HHN BV”), outstanding senior notes to amend and waive certain provisions of the indentures (collectively, the “Indentures”) following which such senior notes were issued. Hertz also declared recently that it is soliciting consents from holders of its wholly-owned partner, Hertz Vehicle Financing LLC’s (“HVF”), outstanding notes to amend and waive certain provisions of its operating lease (“Lease”) with Hertz that secures such notes.
As formerly declared, the formerly issued financial statements of the Company must be restated and should no longer be relied upon. As a result of the completion of Administration’s examination of additional accounts in connection with our accounting review and investigation, the Company has identified an additional $30 million in errors above that which had been formerly identified. As a result, the impact on GAAP pre-tax income of cumulative errors identified to date, on an unaudited basis, is about $42 million, $85 million and $56 million for 2013, 2012 and 2011, respectively, inclusive of $9 million in 2012 and $19 million in 2011, formerly revealed and reflected in the financials comprised of in the Company’s 2013 Form 10-K. The review and investigation of the Company’s financial records are ongoing, and amounts are therefore subject to change based on the completion of the investigation and review, and such changes may be significant.
Hertz Global Holdings, Inc., through its auxiliaries, is engaged in the car and equipment rental businesses worldwide. It operates through four segments: U.S. Car Rental, International Car Rental, Worldwide Equipment Rental, and All Other Operations.
Shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), inclined 5.73% to $6.83, during its last trading session.
Pernix Therapeutics Holdings, declared that the U.S. Food and Drug Administration (FDA) has approved TREXIMET® (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.
TREXIMET is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The two medicines – sumatriptan and naproxen sodium – in combination provide more effective, sustained control of the pain and associated symptoms of migraine contrast to either medicine taken alone. Approval came after the FDA’s review of pivotal phase 3 safety and efficacy clinical trial, plus long-term safety and pharmacokinetic data, demonstrating that TREXIMET is significantly more effective than placebo in treating migraine in pediatric patients and has a favorable safety profile similar to that of TREXIMET for adults. TREXIMET carries a boxed warning noting cardiovascular and gastrointestinal risks. For full safety and efficacy information, please see the prescribing information. While TREXIMET has been approved for the acute treatment of migraine in adults since 2008, the FDA set a precedingity review of the supplemental New Drug Application based, in part, on the need for options among this specialty population. An estimated eight percent to 23 percent of all pediatric patients 11 years and older suffer from migraine7, but treatment options have been limited, especially contrast to adults.
The recommended dose for pediatric patients 12 years of age and older is a single tablet of TREXIMET 10/60 mg (sumatriptan 10 mg and naproxen sodium 60 mg) per 24-hour period and the maximum recommended dose is 85/500 mg per 24-hour period. The recommended dose for adults is a single tablet of TREXIMET 85/500 mg.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product.
At the end of Friday’s trade, Shares of Rex Energy Corporation (NASDAQ:REXX), gained 0.47% to $5.32.
Rex Energy Corporation, declared that it has commenced a registered exchange offer to exchange up to $325 million aggregate principal amount of its 6.250% Senior Notes due 2022, which have been registered under the Securities Act of 1933, as amended (the “Exchange Notes”), for up to $325 million of its outstanding 6.250% Senior Notes due 2022, which were formerly issued in a private placement.
The sole purpose of the exchange offer is to fulfill the Company’s obligations with respect to the registration of the Private Notes. Following a registration rights agreement reached by the Company in connection with the sale of the Private Notes, the Company agreed to file with the Securities and Exchange Commission a registration statement regarding an exchange offer following which Exchange Notes, containing substantially identical terms to the Private Notes, would be offered in exchange for Private Notes that are tendered by the holders of those notes.
The Exchange Offer will expire at 5:00 p.m., New York City time, on June 8, 2015, unless extended. Private Notes tendered following the Exchange Offer may be withdrawn at any time preceding to the expiration date by following the procedures set forth in the prospectus pertaining to the Exchange Offer.
Rex Energy Corporation operates as an independent oil, natural gas liquid, and natural gas company in the Appalachian and Illinois basins in the United States. The company focuses on the Marcellus Shale, Utica Shale, and Burkett Shale drilling and exploration activities in the Appalachian Basin, in addition to on developmental oil drilling and the implementation of improved oil recovery on its properties in the Illinois Basins.
Finally, Costco Wholesale Corporation (NASDAQ:COST), ended its last trade with 1.56% gain, and closed at $144.83.
Costco Wholesale Corporation, stated net sales of $8.75 billion for the month of April, the four weeks ended May 3, 2015, an enhance of two percent from $8.56 billion during the similar period last year. This year’s sales reflects one additional sales day than last year, due to the timing of the Easter holiday. This calendar shift positively influenced this year’s net and comparable sales by an estimated one and one-half to two percent.
For the thirty-five weeks ended May 3, 2015, the Company stated net sales of $76.33 billion, an enhance of four percent from $73.21 billion during the similar period last year.
Costco Wholesale Corporation, together with its auxiliaries, operates membership warehouses. The company offers branded and private-label products in a range of merchandise categories. It provides dry and institutionally packaged foods; snack foods, candy, tobacco, alcoholic and nonalcoholic beverages, and cleaning and institutional supplies; appliances, electronics, health and beauty aids, hardware, garden and patio, and office supplies; meat, bakery, deli, and produce; and apparel, small appliances, and home furnishings.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.